Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06238726 |
Other study ID # |
2023-1504 |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 25, 2024 |
Est. completion date |
May 13, 2025 |
Study information
Verified date |
June 2024 |
Source |
Geisinger Clinic |
Contact |
Amir Goren, PhD |
Phone |
570-214-3495 |
Email |
agoren[@]geisinger.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to test whether messages encouraging patients to ask about a
Shingrix vaccine at an upcoming appointment will increase Shingrix vaccination rates. The
study will also test which of several message versions is most effective.
Description:
Shingles is a painful disease caused by reactivation of the varicella zoster (chickenpox)
virus. About a third of adults in the US will develop shingles in their lifetime, with the
highest prevalence in adults ages 50 and older. Roughly one in ten patients with shingles
develops complications that can lead to long-term pain and inflammation). Shingrix, a
two-shot vaccine series, is highly effective at preventing shingles and is recommended by the
CDC for all adults ages 50 and over.
The present study will test whether sending patients messages encouraging them to ask about
Shingrix at an upcoming primary care appointment increases vaccination rate relative to
Passive Control (no messages). Additionally, four message arms will vary as a function of
risk (message includes or does not include a statement telling patient they are at high risk
for shingles because they are age 50+) and facts (message includes or does not include
several facts about shingles and Shingrix), with the no-high-risk, no-facts arm designated as
the Active Control arm.
Message arms will be crossed with two additional randomized variables: number of messages (2
messages or 3 messages) and cost information (the presence or absence of information about
the cost of Shingrix in the final message).
Enrollment timing will vary by insurance group. Enrollment will begin with patients who have
a Geisinger Health Plan (GHP) membership that allows them to get Shingrix at no cost (this
includes the vast majority of GHP members), because existing data allow the study team to
easily identify these patients and inform them about their Shingrix coverage in cost
messages. Enrollment for patients who are not GHP members (and the few patients with a GHP
plan that is not Shingrix eligible) will begin following the development of an automated
internal process that will allow cost messages to include information about patients'
individualized Shingrix insurance benefits. Alternatively, if development is delayed
approximately 2 months or longer from the launch of enrollment for GHP members, the study
team may decide in collaboration with Geisinger leadership to begin enrolling patients
without GHP using a generic cost message (e.g., "Most patients can get Shingrix at no cost").
Enrollment for each insurance group (GHP members, non-GHP members) will begin with a 2-week
pilot period, with a limited number of new patients (e.g., 100 to 200) enrolled per day in
that insurance group (these patients will be randomly selected from the eligible patients).
During the pilot period, the study team will communicate frequently with clinical partners to
ensure there are no issues before full rollout. If issues arise, the pilot period may be
extended. If the pilot period does not result in any changes to outreach, or involves only
trivial changes, patients enrolled in the pilot period will be included in analysis. If there
are more substantive changes to the outreach following the pilot period, patients enrolled
during that period will be excluded from analysis.
Once full rollout occurs, enrollment for each insurance group will last for 1 year. Study
enrollment will be complete 1 year following full rollout for non-GHP members.
Anticipated enrollment is at least 50,000.
UPDATE ON 4/15/24: Following a recent review of clinical operational workflows, clinical
stakeholders determined that the copays estimated through the automated process will
typically not be applicable to non-GHP members. Therefore, in the coming weeks, text
messaging to eligible non-GHP members will begin, with a generic cost message for those
randomized to be sent a cost message.